Fatty liver is exactly what the name suggests: an abnormal buildup of fat inside liver cells. A healthy liver contains some fat, but when fat accounts for more than about 5% of the liver’s weight, doctors call it steatosis. Whether it’s dangerous depends almost entirely on what happens next. In many people, the fat just sits there. In others, the liver becomes inflamed, scarred, and eventually unable to function. The condition now affects roughly one in three adults worldwide, and the leading cause of death among those who have it is not liver failure but cardiovascular disease.
What Actually Happens Inside a Fatty Liver
The liver normally processes fats that arrive from your diet and from fat tissue elsewhere in your body. It also makes new fat from sugars through a process called de novo lipogenesis. In a healthy liver, the fat coming in roughly balances the fat going out, whether that’s through burning fat for energy or packaging it into particles that get shipped into the bloodstream. Fatty liver develops when that balance tips: more fat arrives or gets made than the liver can burn or export.1PubMed Central. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
The liver tries to compensate by ramping up fat burning, but that compensatory effort comes with a cost. Increased fat oxidation generates more reactive oxygen species, which are chemically aggressive molecules that damage cell structures. When the liver’s antioxidant defenses can’t keep up, that oxidative stress injures liver cells and can push the disease forward.1PubMed Central. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease Dietary factors play a big role: glucose and fructose are major raw materials for new fat production in the liver, while insulin resistance in fat and muscle tissue sends extra fatty acids streaming toward the liver.2PubMed. Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
Why Doctors Changed the Name
For decades, the condition was called non-alcoholic fatty liver disease, or NAFLD. The name defined the disease by what it was not (not caused by alcohol), which was both vague and somewhat stigmatizing. In 2023, a large international consensus group replaced NAFLD with metabolic dysfunction-associated steatotic liver disease, or MASLD. The updated name reflects what the disease actually is: fat accumulation driven by metabolic problems like insulin resistance, excess weight, high blood pressure, or abnormal blood lipids.3PubMed Central. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease You’ll still see the old NAFLD label in many studies and medical records, so both terms refer to essentially the same condition. Throughout this article, both names appear depending on which term the underlying research used.
From Fat to Fibrosis
Simple fat accumulation, often called simple steatosis, is the earliest stage. Many people stay at this stage for years or even their whole lives without serious consequences. The trouble starts when fat accumulation triggers ongoing inflammation, a condition called MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH). In MASH, the buildup of toxic lipid byproducts damages structures inside liver cells, including the mitochondria and the endoplasmic reticulum. That damage promotes oxidative stress and activates inflammatory pathways.4JHEP Reports. Inflammation in MASLD progression and cancer When the liver can no longer keep up with the flood of incoming fat, toxic lipid species accumulate and trigger a cascade of cell injury and cell death.5PubMed. Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
Chronic inflammation activates specialized cells in the liver called hepatic stellate cells. When these cells are switched on, they produce collagen and other fibrous proteins, gradually replacing healthy liver tissue with scar tissue. This scarring is called fibrosis, and it’s the single most important predictor of how a patient with fatty liver will fare long-term.6PubMed Central. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease Fibrosis is graded on a scale from F0 (no scarring) through F4 (cirrhosis). Cirrhosis means the liver is so heavily scarred that its structure is fundamentally altered, and at that point the risk of liver failure and liver cancer rises sharply.7PubMed Central. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
The Real Danger Is Often Outside the Liver
Here is something that surprises most people: the most common cause of death in people with fatty liver disease is not liver-related at all. Cardiovascular disease is the leading killer, followed by cancers outside the liver, then liver-specific causes, and then diabetes.8PubMed Central. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease This makes sense when you consider that fatty liver shares most of its risk factors with heart disease: insulin resistance, high triglycerides, abdominal obesity, and chronic low-grade inflammation. The liver isn’t just a passive victim; when it’s metabolically stressed, it exports inflammatory signals and abnormal lipid particles that accelerate damage in blood vessels, the heart, and other organs.
Liver cancer is still a real concern, and the risk rises steeply with each stage of disease progression. In a large population-based study, the rate of liver cancer increased in a stepwise pattern from simple steatosis through fibrosis to cirrhosis. Patients with cirrhosis had by far the highest risk, but substantial excess risk was also found in people with fibrosis who hadn’t yet reached cirrhosis, especially if they also had diabetes.9PubMed Central. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study About one in five people who develop liver cancer from fatty liver disease have no evidence of cirrhosis at all, which means cancer screening can’t be limited to only those with the most advanced scarring.10PubMed Central. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
Why You Probably Won’t Feel It
Fatty liver is notoriously silent. Most people have no symptoms at all during the early stages, and even when the disease has progressed to MASH, symptoms tend to be vague: fatigue, a dull discomfort in the upper right abdomen, or general malaise that could be attributed to almost anything. The liver doesn’t have pain-sensing nerves inside its tissue; discomfort usually comes from the liver swelling and stretching its outer capsule. Many people learn they have fatty liver only when a routine blood test shows mildly elevated liver enzymes or an imaging scan done for some other reason reveals fat in the liver.
Even liver enzymes are unreliable guides. A study tracking enzyme levels over time in people with biopsy-confirmed fatty liver found that liver enzyme levels were insensitive tools for tracking changes in what’s actually happening inside the liver.11PubMed. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease Your enzymes can look perfectly normal while fibrosis is quietly advancing, or they can spike for reasons unrelated to actual disease progression. This is one of the biggest practical problems with fatty liver: the disease that affects one in three adults usually announces itself only when damage is already underway.
How Doctors Detect and Stage It
Because blood tests alone aren’t reliable for staging, doctors use a combination of non-invasive tools to estimate how much fibrosis is present. The FIB-4 index is a simple scoring system calculated from a patient’s age, platelet count, and two liver enzyme values. It’s cheap, widely available, and performs reasonably well at ruling out advanced fibrosis. At a low cutoff, FIB-4 has very high sensitivity for catching advanced fibrosis, and at a higher cutoff it’s good at confirming it.12PubMed Central. Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring Both FIB-4 and a related tool called the NAFLD fibrosis score also have prognostic value, meaning higher scores predict liver-related events and death over subsequent years.13PubMed Central. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review
FibroScan is a specialized ultrasound-based device that measures liver stiffness, which correlates with fibrosis. A systematic review found it had sensitivity above 90% and specificity above 90% for detecting advanced fibrosis (stage F3 or higher).14PubMed Central. Assessment of transient elastography FibroScan for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis When FibroScan readings are low (below about 8 kPa), doctors can be quite confident there’s no significant fibrosis. When readings are elevated, the picture gets murkier — the positive predictive value for moderate fibrosis is low, meaning an elevated reading often turns out to be a false alarm.15PubMed Central. FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH In practice, these tools are best at ruling out advanced disease rather than confirming it, and when results are ambiguous, a liver biopsy remains the gold standard.
Who Gets Fatty Liver
The strongest risk factors are the metabolic ones: excess body weight (especially visceral abdominal fat), insulin resistance, type 2 diabetes, and high triglycerides. The overlap with diabetes is particularly striking. Fatty liver has been found in roughly 70% of people with type 2 diabetes, and the relationship goes both ways: fatty liver promotes insulin resistance, which worsens diabetes, which in turn drives more fat into the liver.16PubMed Central. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus 17PubMed Central. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship
Genetics matter more than most people realize. A variant in a gene called PNPLA3 is strongly associated with liver fat levels. People who carry two copies of the risk variant have more than double the liver fat content of non-carriers, and this variant is most common in Hispanic populations, which helps explain why fatty liver rates are higher in that group.18Nature Genetics. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Other genetic variants have since been identified, but PNPLA3 remains the most studied and has the largest effect size. If you have a family history of fatty liver disease or liver problems, you may be genetically predisposed even if your weight and metabolic numbers look acceptable.
Lifestyle factors beyond diet and weight also contribute. There’s evidence linking disrupted circadian rhythms, including irregular sleep schedules, shift work, and chronic sleep deprivation, to metabolic syndrome and fatty liver development.19SpringerLink / PubMed Central. Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Menopause and Estrogen
Fatty liver shows a striking sex-based pattern. Before menopause, women develop it less frequently than men. After menopause, rates climb and the gap closes or even reverses. The evidence points to estrogen as a protective factor: estrogen deficiency promotes liver fat accumulation, insulin resistance, and fibrosis, and the prevalence and severity of fatty liver rise significantly in postmenopausal women.20Endocrine Reviews. The Impact of Estrogen Deficiency on Liver Metabolism: Implications for Hormone Replacement Therapy 21PubMed. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives Beyond estrogen loss itself, the shift toward relatively higher androgen levels and lower sex hormone-binding protein in postmenopausal women appears to interact with increased abdominal fat, further accelerating the disease.
How estrogen is replaced may matter. One study found that after 12 months of hormone therapy, fatty liver rates were lower in women using transdermal estrogen (patches or gels) compared to oral estrogen: roughly 17% versus 29%. New or worsening fatty liver also occurred less frequently with the transdermal route.22Scientific Reports. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration The likely explanation is that oral estrogen passes through the liver first and can affect hepatic lipid metabolism differently than estrogen delivered through the skin.
Fatty Liver in Children
This is not solely an adult problem. An autopsy-based study in the United States estimated that roughly 10% of children and adolescents aged 2 to 19 had fatty liver, with rates rising sharply with age: under 1% in toddlers but about 17% by the late teen years. Among obese children, the rate reached 38%.23PubMed. Prevalence of fatty liver in children and adolescents A systematic review and meta-analysis found a pooled prevalence of about 8% in the general pediatric population and about 34% in children attending obesity clinics, with boys more affected than girls.24PLoS ONE. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis These numbers are almost certainly higher now, given rising childhood obesity rates worldwide. Unlike adults who may develop cirrhosis over decades, children diagnosed with fatty liver in their teens face a much longer timeline of potential disease progression ahead of them, which makes early intervention especially important.
Can You Reverse It
The good news is that fatty liver, even with inflammation, can improve substantially with weight loss. The evidence is remarkably consistent on the thresholds. Losing at least 5% of body weight tends to reduce liver fat and improve inflammation. Losing 7–10% has more impact on MASH and fibrosis. In one landmark study, all patients who lost 10% or more of their body weight saw their disease activity scores drop, 90% had complete resolution of MASH, and 45% showed reversal of fibrosis. The catch: only about 10% of participants in the study actually achieved that level of weight loss.25PubMed. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis A systematic review and meta-analysis confirmed a dose-response relationship between weight loss and improvements in liver inflammation and ballooning, though the relationship with fibrosis specifically was less consistent.26Metabolism. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis
Once cirrhosis has set in, the liver’s ability to regenerate is severely limited. Some early-stage cirrhosis can still partially reverse with aggressive intervention, but advanced cirrhosis is generally considered irreversible. This is why catching and addressing fatty liver before it reaches late-stage fibrosis matters so much.
Exercise Without Losing Weight
One of the more encouraging findings in this area is that exercise reduces liver fat even when you don’t lose weight. A systematic review and meta-analysis found that exercise training made patients roughly three and a half times more likely to achieve a meaningful reduction in liver fat compared with standard care, independent of body weight changes.27PubMed Central. Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis The benefit appears to kick in at a moderate volume of activity. Exercise improves how muscles and fat tissue respond to insulin, which reduces the flood of fatty acids heading to the liver. It also directly increases fat burning in the liver and decreases new fat production.28PubMed Central. The Effects of Physical Exercise on Fatty Liver Disease 29PubMed Central. Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis This is practically important because many people with fatty liver struggle to lose weight. Knowing that regular physical activity helps the liver even without the number on the scale moving can be motivating.
What to Eat
The Mediterranean dietary pattern is the most studied and most recommended eating approach for fatty liver. Its core components, including olive oil, fish, nuts, whole grains, fruits, and vegetables, have each been associated with better liver outcomes. Meanwhile, the hallmarks of a Western diet, such as soft drinks, foods high in fructose, red meat, and saturated fats, are associated with worse outcomes.30PubMed. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms The polyunsaturated fats abundant in a Mediterranean diet promote a metabolic shift in the liver: they increase fat burning and suppress the creation of new fat.31PubMed Central. Mediterranean diet and nonalcoholic fatty liver disease Fructose deserves special mention. Unlike glucose, which is metabolized throughout the body, fructose is processed almost exclusively in the liver. High fructose intake from sugary drinks and processed foods is a potent driver of liver fat production, and reducing it is one of the most impactful single dietary changes a person with fatty liver can make.
The Gut-Liver Connection
Your liver receives blood directly from the intestines through the portal vein, which means whatever crosses the gut lining is delivered straight to the liver before reaching the rest of the body. In people with fatty liver, the intestinal barrier is often compromised, a condition sometimes called increased intestinal permeability. When that barrier breaks down, bacterial products leak from the gut into the portal blood and reach the liver, where they trigger immune cells and drive inflammation.32Frontiers in Gastroenterology. Gut microbiome in non-alcoholic fatty liver disease The gut microbiome itself shifts in people with fatty liver: some bacterial populations that produce ethanol internally become more abundant, meaning the liver may be exposed to alcohol produced by the body’s own bacteria even in people who don’t drink.33PubMed Central. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target This gut-liver axis is an active area of research, and future treatments may target intestinal permeability or microbiome composition alongside the liver itself.
When Alcohol and Metabolic Factors Overlap
The old NAFLD label required that patients drink little or no alcohol. The new naming system created an additional category, MetALD, for people who have metabolic risk factors and drink moderate-to-heavy amounts of alcohol. This recognizes a reality that clinicians have always known: many patients fall in between “purely metabolic” and “purely alcohol-related” liver disease.34PubMed. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice The damage from metabolic dysfunction and alcohol is not simply additive. Obesity and insulin resistance alter how the body processes alcohol, increasing its toxicity and amplifying liver damage well beyond what either factor would cause alone.35npj Gut and Liver. Metabolic and alcohol-associated liver disease (MetALD): a representation of duality If you already have metabolic risk factors for fatty liver, even moderate drinking may push your liver harder than you’d expect. The MetALD category is new enough that specific clinical thresholds and long-term outcomes are still being studied, but the basic message is clear: alcohol and metabolic liver stress interact in ways that make each one worse.